Related Experiment Video

Updated: Aug 11, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy

Idris Boudhabhay1,2, Marion Rabant2, Lubka T Roumenina3

  • 1Groupe Hospitalier Sud Ile de France, Service de Réanimation, Melun, France.

Frontiers in Immunology
|July 12, 2021
PubMed

Insights

Multisystem inflammatory syndrome in adults (MIS-A) after COVID-19 may involve thrombotic microangiopathy (TMA). Complement inhibition with eculizumab showed promising results in a patient with post-COVID-19 MIS-A and kidney injury.

Area of Science:

  • Nephrology
  • Immunology
  • Infectious Diseases

Background:

  • The COVID-19 pandemic has led to the emergence of multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A).
  • The underlying pathophysiology of MIS-A following SARS-CoV-2 infection remains largely unknown.
  • Thrombotic microangiopathy (TMA) is a potential, yet unconfirmed, mechanism in MIS-A.

Observation:

  • A case of MIS-A in a 46-year-old male patient post-COVID-19 is presented.
  • The patient exhibited biopsy-proven renal thrombotic microangiopathy (TMA).
  • Prompt initiation of complement inhibition therapy with eculizumab was administered.

Findings:

  • Eculizumab treatment resulted in a significant improvement in the patient's renal function.
  • The case highlights a potential link between TMA and the pathophysiology of post-COVID-19 MIS-A.
  • Complement inhibition emerged as a viable therapeutic strategy.

Implications:

  • Thrombotic microangiopathy (TMA) may play a critical role in the development of post-COVID-19 MIS-A.
  • Complement pathway inhibitors, such as eculizumab, represent a promising therapeutic avenue for MIS-A.
  • Further research into the role of TMA and complement activation in MIS-A is warranted.
Abstract

Keywords:
COVID-19case reportcomplement systemeculizumabmultisystem inflammatory syndromethrombotic microangiopathy

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.4K
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.0K

Related Concept Videos

Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...